RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket billJuly 15, 2024 - "While patent cliffs are looming for many of biopharma’s top-selling products, the industry has enormous capacity to respond as “conditions for M&A are favorable,” according to a research note from Morgan Stanley.
The US Senate's passing of the anti-patent thicket bill on July 12, 2024 will consequently prompt Big Pharma to accelerate and expedite their M&A initiative, since patent layering on top of a single, previously approved product will no longer be possible.